News for Ocular Therapeutix, Inc. (OCUL)

Summary Ocular Therapeutix Inc (OCUL), a biopharmaceutical company focused on innovative treatments for retinal diseases, announced on March 7, 2025, the granti

BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. ( OCUL, ”œOcular”), a biopharmaceutical company committed to redefining the ret

**media[560521]**

On March 5, 2025, Opaleye Management Inc. (Trades, Portfolio) made a strategic move by acquiring an additional 260,000 shares of Codexis Inc. (CDXS). This trans

Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Check out what makes OCUL stock a speculative strong buy.

Strengths: Innovative hydrogel technology and robust product pipeline.Weaknesses: Significant losses and accumulated deficit impacting financial stability.Oppo

Cash Balance: $392 million as of December 31, 2024.Cash Runway: Sufficient to fund planned operating expenses, debt service obligations, and capital expenditur

Mar 03, 2025 / 01:00PM GMTOperator Good morning, and welcome to the Ocular Therapeutix fourth quarter 2024 earnings conference call. (Operator Instructions) As

Ocular Therapeutix Q4 2024 earnings reveal FDA-approved trial updates for AXPAXLI in wet AMD, streamlined designs, and strong cash reserves.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ETCompany ParticipantsBill Slattery - Vice President, Investor...

Ocular Therapeutix Inc (OCUL), a biopharmaceutical company focused on innovative treatments for retinal diseases, announced on February 25, 2025, that it will p

Ocular Therapeutix Inc (OCUL), a biopharmaceutical company focused on innovative treatments for retinal diseases, announced it will host a conference call and w

**media[548312]**

BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. ( OCUL, ”œOcular”), a biopharmaceutical company committed to redefining the reti

On December 31, 2024, Opaleye Management Inc. (Trades, Portfolio) executed a significant transaction involving Ocular Therapeutix Inc. The firm reduced its hold

Opaleye Management Inc. (Trades, Portfolio) recently executed a significant stock transaction, acquiring an additional 375,000 shares of iBio Inc. on December 3

Opaleye Management Inc. (Trades, Portfolio)'s Recent Acquisition On December 31, 2024, Opaleye Management Inc. (Trades, Portfolio) executed a strategic stock tr

Summary Ocular Therapeutix Inc (OCUL), a biopharmaceutical company focused on innovative treatments for retinal diseases, announced its participation in the Ang

On January 22, 2025, Opaleye Management Inc. (Trades, Portfolio) executed a substantial reduction in its holdings of Harrow Inc., a U.S.-based eyecare pharmaceu